Abstract Number: 1056 • 2019 ACR/ARP Annual Meeting
Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway
Background/Purpose: An M2-like alternative activation state of macrophages has been linked to the pathogenesis of several fibrotic disorders, including systemic sclerosis (SSc). MRTF-A is an…Abstract Number: 1058 • 2019 ACR/ARP Annual Meeting
Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis
Background/Purpose: Epigenetic regulation, including histone acetylation, plays an important role in scleroderma (SSc) fibrosis. The binding of the bromodomain and extra-terminal domain proteins (BRDs) to…Abstract Number: 1074 • 2019 ACR/ARP Annual Meeting
Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells
Background/Purpose: Progressive functional and structural vascular disorder is one of the hallmark features of Systemic Sclerosis (Scleroderma, SSc). Vascular dysfunction lead to dysregulated vascular tone…Abstract Number: 1635 • 2019 ACR/ARP Annual Meeting
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
Background/Purpose: To evaluate any correlation between the Raynaud's Condition Score (RCS) and the morphological and functional methods available to evaluate microvascular damage in systemic sclerosis (SSc) patients (1-4). Methods: Sixty-six…Abstract Number: 2745 • 2019 ACR/ARP Annual Meeting
Iguratimod Treated Scleroderma with Interrupted Egr1/TGF-β Loop
Background/Purpose: Iguratimod is a novel disease modifying anti-rheumatic drug that has been approved for treating rheumatoid arthritis in East Asia. Transcription factor early growth response…Abstract Number: 901 • 2018 ACR/ARHP Annual Meeting
Changes in Quantitative Scleroderma Lung CT Measures in Patients Treated with Cyclophosphamide or Transplantation
Background/Purpose: Scleroderma related interstitial lung disease (SLD) is a major cause of morbidity and mortality in severe systemic sclerosis (SSc). The Scleroderma: Cyclophosphamide or Transplantation…Abstract Number: 1423 • 2018 ACR/ARHP Annual Meeting
Autoantibody Testing in Pediatric Localized Scleroderma (LS)
Background/Purpose: Pediatric localized scleroderma (LS) is typically categorized by the depth and extent of skin lesions into main subtypes: linear scleroderma, including linear trunk/limb and…Abstract Number: 1731 • 2018 ACR/ARHP Annual Meeting
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
Background/Purpose: Osteoporosis screening is not systematic in sclerodermic patients but some studies demonstrated a similar risk between rheumatoid arthritis and systemic scleroderma [1,2,3]. Thoracic and/or…Abstract Number: 122 • 2018 ACR/ARHP Annual Meeting
Metformin Inhibited the Development of Bleomycin-Induced Murine Scleroderma Via Restoring the Balance between Regulatory and Effector T Cells and Suppressing Spleen Germinal Center Formation
Background/Purpose: Scleroderma is a multisystem connective tissue disease characterized by extensive tissue fibrosis and its three prominent cardinal features are vasculopathy, excessive collagen deposition and immunological abnormalities. Metformin (MET)…Abstract Number: 98 • 2017 ACR/ARHP Annual Meeting
Impact of a Lung Ultrasound Course for Rheumatology Specialist (IMPACT-2)
Background/Purpose: Although much emphasis is focused on lung ultrasonography(US) within the critical care field, there is a growing interest in the use of lung…Abstract Number: 754 • 2017 ACR/ARHP Annual Meeting
Interferon Siganture in Systemic Sclerosis Lung Microvascular Endothelial Cells
Background/Purpose: Systemic Sclerosis (SSc) is characterized by severe fibroproliferative vasculopathy, exaggerated deposition of extracellular matrix molecules (ECM) in skin and multiple internal organs, and alterations…Abstract Number: 765 • 2017 ACR/ARHP Annual Meeting
Proteomic Analysis of Scleroderma Associated Joint Disease
Background/Purpose: The pathophysiology of joint disease in scleroderma, a heterogeneous multisystem disease mostly characterized by fibrosis, is unknown. We performed proteomic analysis of serum in…Abstract Number: 1258 • 2017 ACR/ARHP Annual Meeting
Divided By a Common Language: Challenges in Physician-Patient Communication Limit Patient Understanding and Support in Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD)
Background/Purpose: Systemic sclerosis is a potentially life-threatening, clinically diverse, and rare condition. The prognosis and course of disease is difficult to predict and treatment is…Abstract Number: 1724 • 2017 ACR/ARHP Annual Meeting
Metabolic Regulation of Fibrosis in Systemic Sclerosis: The CD38-NAD+ Link
Background/Purpose: The anti-aging deacetylase enzymes SIRT1 and SIRT3 show potent anti-fibrotic activity, and their expression and function are markedly deregulated in patients with systemic sclerosis…Abstract Number: 820 • 2016 ACR/ARHP Annual Meeting
EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma
Background/Purpose: Scleroderma (SSc) is a complex disease that involves activation of the immune system, vascular complications, and tissue fibrosis. Although the pathogenesis of this disease…